Claims
- 1. A polypeptide selected from the group consisting of:
(a) amino acids 37-140 of SEQ ID NO:9 (NBN 104); (b) amino acids 39-140 of SEQ ID NO:9 (NBN 102); and (c) amino acids 42-140 of SEQ ID NO:9 (NBN 99).
- 2. The polypeptide of claim 1, wherein the amino acid sequence consists of amino acids 37-140 of SEQ ID NO:9 (NBN 104).
- 3. A nucleic acid that encodes a polypeptide of claim 1 or 2.
- 4. A vector comprising the nucleic acid of claim 3.
- 5. A host cell transformed with the vector of claim 4.
- 6. The host cell of claim 5, wherein the host cell is a Chinese hamster ovary cell.
- 7. A method of making the polypeptide of claim 1, comprising: (a) providing a host cell transformed with an expression vector comprising a nucleic acid encoding the polypeptide of claim 1, (b) culturing the host cell, and (c) recovering the polypeptide.
- 8. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
- 9. A method of treating a peripheral neuropathy or neuropathic pain in a mammal, comprising administering to the mammal a therapeutically effective amount of the composition of claim 8.
- 10. The method of claim 9, wherein the composition is administered systemically.
RELATED APPLICATIONS
[0001] This is a continuation of PCT/EP02/02691, filed on Mar. 11, 2002, which claims priority from U.S. patent application Ser. No. 09/804,615 filed on Mar. 12, 2001.
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/EP02/02691 |
Mar 2002 |
US |
Child |
10661984 |
Sep 2003 |
US |